Please assess the completion status of the following clinical trial:

Trial Title: Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of 1 of the following hematologic malignancies:~  * Acute myeloid leukemia (AML) with or without history of myelodysplastic syndromes, meeting 1 of the following criteria:~    * In first complete remission (CR-1) with unfavorable cytogenetics and/or achieved CR-1 after ≥ 1 course of induction therapy~   * Secondary or treatment-related AML~   * In second or further complete remission~   * Relapsed with ≤ 20% blasts in the bone marrow AND no circulating blasts~ * Acute lymphoblastic leukemia (ALL), meeting 1 of the following criteria:~    * In CR-1 with unfavorable cytogenetics or elevated WBC at presentation OR failed to achieve CR-1 after ≥ 4 weeks of induction therapy~   * In second or further complete remission~   * Relapsed with ≤ 20% blasts in the bone marrow AND no circulating blasts~ * Other acute leukemic variants allowed at the discretion of the principal investigator~ * Chronic myelogenous leukemia (CML), meeting 1 of the following criteria:~    * In first chronic phase AND refractory to or unable to tolerate imatinib mesylate~   * In second or further chronic phase~   * In first or second accelerated phase~ * Myelodysplastic syndromes with intermediate 2- or high-risk International Prognosis Scoring System (IPSS) score, including any of the following:~    * Refractory anemia~   * Refractory anemia with excess blasts~   * Chronic myelomonocytic leukemia~ * Myeloproliferative disorders with poor prognosis, including any of the following:~    * Myelofibrosis with myeloid metaplasia~      * No ≥ grade 3 myelofibrosis~   * Atypical CML~   * Juvenile myelomonocytic leukemia~ * Other clonal hemopathies with an accepted poor prognosis~ * Multiple myeloma with chromosome 13 abnormalities and/or progression after prior autologous bone marrow transplantation (BMT)~ * Chronic lymphocytic leukemia, meeting 1 of the following criteria:~    * Primary refractory OR relapsed and refractory disease (less than partial remission)~   * Relapsed twice on or after prior chemotherapy~ * Lymphoma, meeting both of the following criteria:~    * Hodgkin's or non-Hodgkin's lymphoma in \> CR-1 OR failed primary induction~   * Chemosensitive disease, defined as \> 50% reduction in mass size after the most recent chemotherapy~* Must meet ≥ 1 of the following criteria:~  * Over 45 years of age~ * Has undergone prior autologous or allogeneic BMT~ * Charlson\^ comorbidity score ≥ 2~* Must have a high degree of tumor control (salvage therapy allowed)~* At high risk for treatment-related mortality with a myeloablative conditioning regimen~* No massive splenomegaly~  * Patients may become eligible after splenectomy or radiotherapy to the spleen~* No 5/6 or 6/6 HLA-matched related donor available~* No well-matched (i.e., ≥ 9/10 HLA match by high-resolution typing) unrelated donor available~PATIENT CHARACTERISTICS:~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* See Disease Characteristics~Hepatic~* Bilirubin ≤ 2 times upper limit of normal (ULN)~* Transaminases ≤ 4 times ULN (unless due to underlying disease)~Renal~* Creatinine clearance ≥ 50 mL/min~Cardiovascular~* Ejection fraction ≥ 30%~Pulmonary~* DCLO ≥ 35%~Other~* Negative pregnancy test~* No uncontrolled viral, bacterial, or fungal infection~* HIV negative~PRIOR CONCURRENT THERAPY:~Biologic therapy~* See Disease Characteristics~Chemotherapy~* See Disease Characteristics~Radiotherapy~* See Disease Characteristics~Other~* At least 3 months since prior immunosuppressive therapy~* At least 10 days since prior salvage therapy for patients not in at least morphologic or radiologic complete remission

- Gender: ALL
- Minimum Age: None
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Conditioning therapy followed by TBI (Type: EXPERIMENTAL): Fludarabine, Cyclophosphamide; Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil

Based on this trial design, predict the completion outcome and termination type (if applicable).